Press Releases Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-08 EDT			5-day change	1st Jan Change
7.92 ^USD	-2.58%		+7.76%	+74.07%

03-19	North American Morning Briefing : Stock Futures -2-	DJ
03-14	Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Larimar: Q4 Earnings Snapshot	03-14	AQ
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development	03-14	AQ
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia	03-11	AQ
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference	03-06	AQ
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares	02-16	AQ
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock	02-14	AQ
Larimar Therapeutics Announces Proposed Underwritten Public Offering	02-13	AQ
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia	02-12	AQ
Larimar: Q3 Earnings Snapshot	11-14	AQ
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results	11-14	AQ
Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology and Immunology Conference	11-02	AQ
Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference	11-01	AQ
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors	23-10-03	AQ
Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference	23-08-31	AQ
Larimar: Q2 Earnings Snapshot	23-08-10	AQ
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results	23-08-10	AQ
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial	23-07-26	AQ
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial	23-07-25	AQ
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer	23-07-17	AQ
Larimar Therapeutics Set to Join Russell 3000® Index	23-06-21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Press Releases

Filters